Navigation Links
Controversial theory of Alzheimer's origin funded
Date:1/25/2008

MELBOURNE, FLA. Dr. Shaohua Xu, Florida Tech associate professor of biological sciences, has an original theory of the origin of Alzheimers Disease and has earned a $150,000 grant from Space Florida to test it. The grant was matched with $30,000 from NASAs Aerospace Medicine and Occupational Health Branch.

He is also the sole medical researcher at the State of Floridas Space Life Sciences Laboratory at Kennedy Space Center (KSC) and the research is being conducted both at the university and KSC.

Xus theory, both controversial and praised, involves the start of the disease when molecules of a normal brain cell protein called tau do something very abnormal: they join together to form tangled fibers that the cell cannot remove. The fibers accumulate until essential substances cannot move through the cell and the cell dies, creating onset of the disease.

Using atomic force microscopy, Xu has studied for the first time the actual process by which the fibers form. Xu uses purified proteins to synthesize the fibers into their various forms.

We find that it is a three-step process, he says. First, molecules of the tau protein cluster together into spheres, each almost the same size. Next, the spheres join together in linear chains like beads on a string. In the third stage the beads merge together to form a uniform filament identical to those found in the brains of patients with the disease.

Advocates of Xus theory are numerous. Daniel Woodard, KSC physician, was the first medical doctor to review the research. He says, Shaohuas theory is revolutionary; his evidence is overwhelming. The medical implications are beyond anything in my experience.

NASA physician David Tipton, chief of the Aerospace Medicine and Environmental Health Branch at KSC, says, This could be the most important biomedical discovery ever made at Kennedy Space Center.

Additionally, Pamela Tronetti, medical director of the Parrish Senior Consultative Center, predicts, If this theory is correct, it may very well have as great an impact on neurodegenerative disease as the discovery of germs had on infection.

The more common theory of Alzheimers origin is that the filaments form by the addition of individual tau molecules to the tip of the fiber.

From our own observations, we believe this theory is incorrect, says Xu. The process we have observed closely resembles that of colloid formation, mixtures like milk or ink in which tiny particles are suspended in a fluid. Our theory is based on colloid science.

Xu affirms that if his theory is correct, it may be possible to halt the disease with drugs that hinder the aggregation of the spherical colloidal particles into linear chains. Similar chemicals are already used to stabilize colloidal materials such as paints.

Xu began developing this theory in 1997, when he conducted Mad Cow Disease research at the University of Chicago. The research continues to have applications for Mad Cow Disease as well as Parkinsons Disease, both of which appear to have very similar mechanisms. Xu will be testing potential drugs that may be able to halt the formation of the filaments.


'/>"/>

Contact: Karen Rhine
krhine@fit.edu
321-698-3279
Florida Institute of Technology
Source:Eurekalert

Related medicine news :

1. Controversial Anemia Drug Doesnt Cut Need for Transfusions
2. Controversial physical agents directive postponed
3. Study Supports Controversial Heart Failure Drug
4. Controversial New Report Details Successes and Challenges as the Microcredit Movement Escalates Its Battle With Poverty
5. Study Puts 1 Alzheimers Theory in Doubt
6. Discovery supports theory of Alzheimers disease as form of diabetes
7. Carnegie Mellon neuroscientist proposes new theory of brain flexibility
8. Research may unlock mystery of autisms origin in the brain
9. Susan G. Komen for the Cure Partners With the Original Butter Bell(R) Crock Developer
10. Worm Study Points to Sexualitys Origins
11. Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics Tissue of Origin Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... serving San Francisco and environs, is proud to announce an upgrade to the ... on the upgraded Yelp page on topics as diverse as Platelet Rich Plasma ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based ... and Palo Alto, is proud to announce an important upgrade to its geographic information ... home care close to home, and by having city-specific pages, NuevaCare is answering that ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports improved ... study released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. ... effective in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao ...
(Date:2/24/2017)... ... 2017 , ... Only two months after the official release of The Private ... (France), XO Private has initiated a second print-run of its lavish luxury travel coffee ... across when open, weighs in at more than six kilos, retails at EUR 1,000 ...
(Date:2/24/2017)... ... ... In the Health Care IT campaign, Robert Herjavec discusses health IT security ... will be attacked, but when.” However, he and many others involved highlight a promising ... in auditing and monitoring have taken security in health care a very long way. ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017  Interpace Diagnostics Group, ... provides clinically useful molecular diagnostic tests and pathology services, ... presented at the upcoming United States ... held March 4-10, 2017 in San Antonio, ... a review of data from the Company,s extensive experience ...
(Date:2/27/2017)... Fla. , Feb. 27, 2017 ... focused on developing cerebral embolic protection devices for ... the FDA,s Circulatory System Devices Panel that convened ... need for cerebral protection following transcatheter aortic valve ... by this FDA panel support the need for ...
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
Breaking Medicine Technology: